1111 Main Street
300 articles with CytoDyn
CytoDyn has spent the past two years under siege. In an exclusive interview, Cyrus Arman, president, told BioSpace how the company is looking to turn the page.
CytoDyn to Hold Webcast to Discuss the Performance of Leronlimab in Clinical Trials and Recent Charges Against Former CEO
CytoDyn Inc. will hold a webcast on December 29, 2022 at 8:00 a.m. Pacific Time (11:00 a.m. Eastern Time) to discuss the performance of leronlimab in its clinical trials and the recent charges against its former CEO Nader Pourhassan, who was previously terminated on January 24, 2022, and has had no affiliation with the Company since that time.
The U.S. Department of Justice indicted former CytoDyn Inc. CEO Nader Z. Pourhassan and the CEO of Amarex Clinical Research on multiple counts of fraud.
CytoDyn to Host R&D Update on Wednesday, December 7, 2022
CytoDyn Inc. announced today that it will host a virtual R&D Update on Wednesday, December 7, 2022, beginning at 11:00 a.m. Eastern Time / 8:00 a.m. Pacific Time.
CytoDyn withdrew its pending Biologics License Application for leronlimab in HIV, citing concerns involving the contract research organization managing its trials.
CytoDyn Announces Voluntary Withdrawal of BLA for HIV-MDR Due to CRO Data Management Issues
CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company") today announced that it has voluntarily withdrawn its pending Biologics License Application (BLA) for leronlimab as a combination therapy in persons living with HIV with resistance to highly active antiretroviral therapy (HAART) in the HIV multi-drug resistant population (HIV-MDR).
CytoDyn Announces Appointment of Additional Directors with Industry Experience
CytoDyn Inc. (OTCQB: CYDY) (“CytoDyn” or the “Company”), a biotechnology company developing leronlimab, a CCR5 antagonist with the potential for multiple therapeutic indications, today announced additional changes in its Board of Directors (the “Board”).
New leaders and top executive roles were selected to guide biopharma and life science companies from Apertura Gene Therapy to CytoDyn, Vaccentis AG, Suvoda LLC, IN8bio and more.
CytoDyn Inc. has tapped Cyrus Arman as its new president and he is expected to take over the reins of the company as chief executive officer and be added to the board of directors within six months.
CytoDyn Appoints Cyrus Arman, Ph.D., MBA, as President
CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a biotechnology company developing leronlimab, a CCR5 antagonist with the potential for multiple therapeutic indications, today announced the appointment of Dr. Cyrus Arman as President effective July 9, 2022.
CytoDyn Highlights NIH Grant for HIV Functional Cure Preclinical Study of Gene Therapy Based on Leronlimab
$5 Million Grant Awarded to OHSU for Preclinical Research of One-time Injection of Gene Therapy Based on Leronlimab for Functional Cure of HIV.
CytoDyn to Hold Webcast to Provide a Quarterly Company Update
CytoDyn Inc. announced today that Tanya Urbach, Board Chair will host an investment community webcast to provide a quarterly Company update on Thursday, June 30, 2022.
CytoDyn Announces Resolution of Legal Dispute with Former Chief Medical Officer
CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a biotechnology company developing leronlimab, a CCR5 antagonist with the potential for multiple therapeutic indications, today announced that it has reached a non-cash settlement with its former Chief Medical Officer, Dr. Richard Pestell, concerning an ongoing legal dispute related to his former employment with the Company.
CytoDyn Announces the Addition of Leading Experts in Oncology, Infectious Diseases, and Neuroinflammation to its Scientific Board of Advisors; Dr. Jay Lalezari to Serve as Outside Scientific Advisor
CytoDyn Inc. announced the addition of Dr. Paul Edison, Dr. Kabir Mody, and Dr. Otto Yang to the Company’s Scientific Board of Advisors.
CytoDyn Announces Publication of Peer-Reviewed Paper, “Suppression of Human and Simian Immunodeficiency Virus Replication with the CCR5-Specific Antibody Leronlimab in Two Species”
CytoDyn Inc. today announced the publication of a peer-reviewed research paper entitled “Suppression of human and simian immunodeficiency virus replication with the CCR5-specific antibody Leronlimab in two species” in the open-access journal PLOS Pathogens.
It was a particularly busy week for clinical trial announcements. Let's take a look.
The U.S. FDA placed a partial hold on CytoDyn's HIV program and a full clinical hold on its COVID-19 program in the U.S.
CytoDyn to Hold Webcast to Provide Company Update - Mar 30, 2022
CytoDyn Inc. announced that Tanya Urbach, Board Chair, Antonio Migliarese, Chief Financial Officer and Interim President, Scott Kelly, Chief Medical Officer and Head of Business Development, and Christopher Recknor, M.D., Senior Executive VP of Clinical Operations, will host an investment community webcast to provide an update on developments at the Company on Thursday, March 31, 2022.
CytoDyn Announces Partial Clinical Hold of HIV Program and Full Clinical Hold of COVID-19 Program
CytoDyn Inc. announced that the U.S. Food and Drug Administration has placed a partial clinical hold on its HIV program and a full clinical hold on its COVID-19 program in the United States.
The same advantage against HIV-1 possessed by a person with the inactive CCR5 variant potentially doubles as resistance to any virus that capitalizes on or manipulates that receptor.